Web Connected Biologistics: Cold Chain Lessons Learned From Pharma
There is an unfortunate and deep-seated mind-set pervasive among many in the traditional drug manufacturing industry; that ones’ responsibility to the product ends at their dock door.
In truth, shipping a drug product – particularly one that is both time-and temperature-sensitive – is only the beginning of a long and circuitous journey where the variety of potential threats and challenges increases and risks to product quality are heightened the further the product travels from its origin.
Typically, a package is left to bumble blindly and blithely through a complex supply chain to its ultimate and eventual destination – an awaiting and grateful patient. The probability that the quality of the product could, to an unquantifiable degree, become compromised along the way is real and warrants a risk-mitigation and management best practices approach. Patients deserve better.
We can – and should – do all possible to employ evidence-based best practices in the commercialization, distribution, delivery, and administration of cell and tissue-based regenerative medicine products.